<DOC>
	<DOC>NCT01784523</DOC>
	<brief_summary>In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.</brief_summary>
	<brief_title>Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients</brief_title>
	<detailed_description>Randomized to receive HCQ or no treatment in addition to their standard regimen. 11 study visits and 10 phone visits over 5 years.</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Antibodies, Antiphospholipid</mesh_term>
	<criteria>Persistent(at least 12 weeks apart)aPLpositivity within 12 months prior to the screening defined as: aCL IgG/M (&gt;40U,mediumtohigh titer,and/or greater than the 99th percentile)and/or aÎ²2GPI IgG/M(&gt;40U, mediumtohigh titer, and/or greater than the 99th percentile)and/or Positive LA test based on the International Society of Thrombosis &amp; Haematosis Recommendations Selected History of thrombosis (arterial, venous, and/or biopsy proven microthrombosis History of Transient Ischemic Attack Confirmed by a Neurologist SLE Diagnosis based on the ACR Classification Criteria &gt; 4/11 Other Systemic Autoimmune Diseases diagnosed based on ACR Classification Criteria Current Hydroxychloroquine or another antimalarial treatment (3 months) Current warfarin treatment (3 months) Current heparin therapy( 3 months) Current pregnancy History of Hydroxychloroquine eye toxicity History of Hydroxychloroquine allergy Known glucose6phosphate dehydrogenase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>antiphospholipid autoantibodies</keyword>
	<keyword>antiphospholipid positive</keyword>
</DOC>